Toripalimab, which has potent anti-tumor effects, was first approved for the second-line treatment of metastatic melanoma in China in December 2018, and for the treatment of patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC) who have previously failed second-line or more systemic therapy in China in February 2021, toripalimab is a humanized IgG4K monoclonal antibody against PD-1, which has provided significant clinical efficacy and a favorable safety profile in various solid tumours. Here, RPL17 is linked to nasopharyngeal carcinoma.